2 Pharma Stocks Flashing Bullish Signals

The 80-day trendline has bullish implications for both MRK and AMRN

by Patrick Martin

Published on Dec 19, 2018 at 12:30 PM

Despite today's gains, the healthcare sector has been under pressure lately amid the recent Obamacare court ruling. If history is any guide though, there could be clear skies ahead for blue chip Merck & Co., Inc. (NYSE:MRK) and cardiovascular disease specialist Amarin Corporation (NASDAQ:AMRN), both of which are flashing the same bullish signal.

MRK Could Test Multi-Year Highs to Start 2019

Merck stock, at last check, was trading up 0.6% at $74.81, and is now within one standard deviation of its 80-day moving average after a lengthy period above it. Over the past three years, there have been six similar encounters with this trendline, after which MRK went on to average a one-month gain of 5.34% and was higher 83% of the time, per data from Schaeffer's Senior Quantitative Analyst Rocky White.

A move of similar proportions would put Merck stock back near $78.80, just a chip-shot from its 17-year high of $80.19 nabbed on Dec. 4. Overall, MRK boasts a 32% gain in 2018, carving out a channel of higher highs since an early April bottom near $53. During this stretch, and even as the broader stock market has swooned, the Dow name has rattled off nine straight monthly wins. 

Daily Stock Chart MRK

In the options pits, the security's Schaeffer's put/call open interest ratio (SOIR) comes in at 1.61, which ranks 1 percentage point from an annual high. In other words, options traders seem relatively pessimistic, with data showing a much higher-than-normal preference for near-term puts over calls. Should MRK once again bounce, an exodus of option bears could be beneficial.

AMRN Set to Snap Skid, Bounce Higher

Looking at Amarin, the stock is also within one standard deviation of its 80-day moving average. Over the past few years, there have been four similar dips to this moving average, after which AMRN went on to average a one-month gain of 11.93%, and was higher 75% of the time, per data from White.

Amarin stock, at last check, was up 3.5% at $15.41, on track to snap a four-day losing streak. A bounce of similar magnitude would have the drugmaker back above $17.20 to start 2019. AMRN has nearly tripled year-to-date, sparked by a late-September bull gap following upbeat data for its heart disease treatment.

Daily Stock Chart AMRN

What's more, traders looking to speculate on AMRN's near-term trajectory should consider options. The stock's Schaeffer's Volatility Index (SVI) of 92% is in just the 8th percentile of its annual range, suggesting short-term options are pricing in relatively low volatility expectations for the shares. In other words, Amarin near-term options are attractively priced at the moment.

PETQ Stock Rallies After ICR Conference
Jefferies reiterated its belief in PETQ stock after the presentation
Bank Earnings Season Sparks Heavy Options Trading
Goldman Sachs earnings are in focus today
Netflix Options Traders Bet On Outsized Earnings Move
NFLX will report earnings after tomorrow's close

a schaeffer's exclusive


Access your FREE insider report before it's too late!


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

IRA/401K Investment Guide: 2019 Stock Market Crash
Use gold to protect any IRA, 401(k), or retirement account from a looming financial crisis.
Star Wars Scare Sparks EA Options Activity; Earnings Beat Helps UAL Take Off
TBLT is the best stock on the Nasdaq today, tripling on a partnership
Morgan Stanley Backs Troubled Chinese E-Commerce Stock
Pinduoduo has had a drama-filled history on Wall Street
Research Exposes Shortcut to Stock Market Riches
A simple way to stop picking losers, and start cashing in like Wall Street's elite.